异源 SARS-CoV-2 加强疫苗在完成 SARS-CoV-2 mRNA 疫苗系列接种后用于血液系统恶性肿瘤患者。
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
出版信息
Vaccine. 2024 Sep 17;42(22):126054. doi: 10.1016/j.vaccine.2024.05.081. Epub 2024 Jun 10.
Heterologous COVID-19 vaccine boosters have not been evaluated for patients with hematological malignancies. A Novavax booster was administered for 56 individuals with hematological malignancies who had received a primary COVID-19 series and prior boosters with mRNA vaccines only. Blood specimens were obtained at baseline (pre-vaccine), 28 days, and 168 days after vaccination with the Novavax booster. The median fold change of anti-Spike IgG was 1.02 (IQR 0.79, 1.3) between baseline and Day 28. Circulating Spike protein-specific B cells increased 1.4-fold at Day 28 (p < 0.05). Increases in antibody and T cell responses were modest without significance, with a waning of humoral and cellular responses at 168 days after vaccination.
尚未评估异体 COVID-19 疫苗加强针在血液恶性肿瘤患者中的效果。对仅接受过 mRNA 疫苗的初级 COVID-19 系列和先前加强针接种的 56 例血液恶性肿瘤患者给予 Novavax 加强针。在接种 Novavax 加强针前（疫苗接种前）、第 28 天和第 168 天采集血液标本。与基线相比，抗刺突 IgG 的中位数 fold change 为 1.02（IQR 0.79, 1.3）在第 28 天。循环 Spike 蛋白特异性 B 细胞在第 28 天增加了 1.4 倍（p < 0.05）。抗体和 T 细胞反应的增加并不显著，在接种后 168 天，体液和细胞反应减弱。
Zotero 插件